Baillie Gifford & Co’s ASLAN Pharmaceuticals Limited American Depositary Shares ASLN Stock Holding History

Baillie Gifford & Co’s Portfolio ASLN Stock Details ASLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10,467	Closed	-$724K	–	229
2019 Q3	$724K	Sell	10,467 -257	-2%	-$26.2K	﹤0.01%	209
2019 Q2	$1.32M	Sell	10,724 -331	-3%	-$49K	﹤0.01%	212
2019 Q1	$1.84M	Sell	11,055 -198	-2%	-$29.5K	﹤0.01%	210
2018 Q4	$1.78M	Hold	11,253	–	–	﹤0.01%	209
2018 Q3	$3.46M	Hold	11,253	–	–	﹤0.01%	205
2018 Q2	$3.96M	Buy	+11,253	New	+$3.49M	﹤0.01%	193

Other funds holding ASLN

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baillie Gifford & Co's ASLN Position: Q4 2019 in Review

Baillie Gifford & Co sold out of ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) in Q4 2019, closing a stake of 10,467 shares — an estimated $724K sold.

Baillie Gifford & Co first reported a position in ASLN in Q2 2018 and held it in 6 quarters. The position peaked at $3.96M in Q2 2018. 15 funds tracked by Wall St. Rank hold ASLN as of Q4 2019.

Baillie Gifford & Co reported no remaining ASLAN Pharmaceuticals Limited American Depositary Shares position as of Q4 2019 after selling out during the quarter.
Baillie Gifford & Co sold 10,467 ASLAN Pharmaceuticals Limited American Depositary Shares shares in Q4 2019, an estimated $724K.
Baillie Gifford & Co first reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares in Q2 2018 and held it in 6 quarters.
Baillie Gifford & Co's ASLAN Pharmaceuticals Limited American Depositary Shares position peaked at $3.96M in Q2 2018.
15 funds tracked by Wall St. Rank held ASLAN Pharmaceuticals Limited American Depositary Shares as of Q4 2019.

Based on Baillie Gifford & Co's 13F filing for Q4 2019, filed 10 Feb 2020.